Form 144 Filer Information UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

**FORM 144** 

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

#### 144: Filer Information

Filer CIK 0001450485
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name

Phone

E-Mail Address

Address of Issuer

#### 144: Issuer Information

Name of Issuer EyePoint Pharmaceuticals, Inc.

SEC File Number 000-51122

480 PLEASANT STREET

SUITE B300 WATERTOWN

MASSACHUSETTS

02472

Phone 617-926-5000

Name of Person for Whose Account the Securities are To Be Sold

Lurker Nancy

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

## 144: Securities Information

| Title of the Class of<br>Securities To Be Sold | Name and Address of<br>the Broker  | Number of<br>Shares or<br>Other Units<br>To Be Sold | Aggregate<br>Market<br>Value | Number of<br>Shares or<br>Other Units<br>Outstanding | Approximate<br>Date of Sale | Name the<br>Securities<br>Exchange |
|--|--|---|------------------------------|--|-----------------------------|------------------------------------|
| Common Stock                                   | Fidelity Brokerage<br>Services LLC<br>245 Summer Street<br>Boston MA 02110 | 5044  | 125949.69                    | 35309432   | 01/23/2024                  | NASDAQ                             |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

### 144: Securities To Be Sold

| Title of the | Date you | Nature of   | Name of Person | Is   | Date  | Amount of  | Date of        | Nature of |
|--------------|----------|-------------|----------------|------|-------|------------|----------------|-----------|
| Class        | Acquired | Acquisition | from Whom      | this | Donor | Securities | <b>Payment</b> | Payment * |

|                         | Transaction                   | Acquired                       | a Acquired Gift? | <b>Acquired</b> |                                 |
|-------------------------|-------------------------------|--------------------------------|------------------|-----------------|---------------------------------|
| Common Stock 10/12/2019 | Open Market<br>Purchase/RSU's | Open Market<br>Purchase/Issuer |                  | 1443            | 10/12/2019 Cash/Stock<br>Option |
| Common Stock 01/31/2020 |                               | Open Market<br>Purchase/Issuer |                  | 2517            | 01/31/2020 Cash/Stock<br>Option |
| Common Stock 02/21/2020 | Open Market<br>Purchase/RSU's | Open Market<br>Purchase/Issuer |                  | 1084            | 02/21/2020 Cash/Stock<br>Option |

<sup>\*</sup> If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

# 144: Securities Sold During The Past 3 Months

| Name and Address of Seller   | Title of Securities Sold | Date of<br>Sale | Amount of<br>Securities<br>Sold | <b>Gross Proceeds</b> |
|--|--------------------------|-----------------|---------------------------------|-----------------------|
| Nancy Lurker<br>c/o EyePoint Pharmaceuticals, Inc.<br>480 Pleasant Street,<br>Watertown MA 02472 | Common Stock             | 12/04/2023      | 20000                           | 415164.00             |

## 144: Remarks and Signature

Remarks

Date of Notice 01/23/2024

Date of Plan Adoption or Giving of Instruction, 05/23/2023

If Relying on Rule 10b5-1

**ATTENTION:** 

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Myra King, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Nancy Lurker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)